Molecular determinants of context-dependent progesterone receptor action in breast cancer
- PMID: 24552158
- PMCID: PMC3929904
- DOI: 10.1186/1741-7015-12-32
Molecular determinants of context-dependent progesterone receptor action in breast cancer
Abstract
The ovarian steroid hormone, progesterone, and its nuclear receptor, the progesterone receptor, are implicated in the progression of breast cancer. Clinical trial data on the effects of hormone replacement therapy underscore the importance of understanding how progestins influence breast cancer growth. The progesterone receptor regulation of distinct target genes is mediated by complex interactions between the progesterone receptor and other regulatory factors that determine the context-dependent transcriptional action of the progesterone receptor. These interactions often lead to post-translational modifications to the progesterone receptor that can dramatically alter receptor function, both in the normal mammary gland and in breast cancer. This review highlights the molecular components that regulate progesterone receptor transcriptional action and describes how a better understanding of the complex interactions between the progesterone receptor and other regulatory factors may be critical to enhancing the clinical efficacy of anti-progestins for use in the treatment of breast cancer.
Figures


Similar articles
-
Mechanism of action of progesterone antagonists.Exp Biol Med (Maywood). 2002 Dec;227(11):969-80. doi: 10.1177/153537020222701104. Exp Biol Med (Maywood). 2002. PMID: 12486206 Review.
-
Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.Oncogene. 2003 Oct 9;22(44):6937-41. doi: 10.1038/sj.onc.1206803. Oncogene. 2003. PMID: 14534541
-
Steroid hormones, steroid receptors, and breast cancer stem cells.J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):39-50. doi: 10.1007/s10911-015-9340-5. Epub 2015 Aug 12. J Mammary Gland Biol Neoplasia. 2015. PMID: 26265122 Free PMC article. Review.
-
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.Steroids. 2000 Oct-Nov;65(10-11):825-30. doi: 10.1016/s0039-128x(00)00195-1. Steroids. 2000. PMID: 11108894 Review.
-
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.J Biol Chem. 2002 Feb 15;277(7):5209-18. doi: 10.1074/jbc.M110090200. Epub 2001 Nov 20. J Biol Chem. 2002. PMID: 11717311
Cited by
-
Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.Front Endocrinol (Lausanne). 2021 Dec 17;12:781066. doi: 10.3389/fendo.2021.781066. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34975755 Free PMC article. Review.
-
Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.ESMO Open. 2016 Aug 22;1(4):e000072. doi: 10.1136/esmoopen-2016-000072. eCollection 2016. ESMO Open. 2016. PMID: 27843626 Free PMC article.
-
Targeting Glycolysis for Treatment of Breast Cancer Resistance: Current Progress and Future Prospects.Int J Biol Sci. 2025 Mar 24;21(6):2589-2605. doi: 10.7150/ijbs.109803. eCollection 2025. Int J Biol Sci. 2025. PMID: 40303296 Free PMC article. Review.
-
Phospho-PR Isoforms and Cancer Stem Cells: What Does the FOXO1 Say?Endocrinology. 2019 May 1;160(5):1067-1068. doi: 10.1210/en.2019-00158. Endocrinology. 2019. PMID: 30901022 Free PMC article. No abstract available.
-
Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.Neurosurg Rev. 2019 Jun;42(2):351-369. doi: 10.1007/s10143-018-0953-1. Epub 2018 Feb 17. Neurosurg Rev. 2019. PMID: 29453736 Review.
References
-
- Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer. 2013;13:385–396. - PubMed
-
- Kraus WL, Montano MM, Katzenellenbogen BS. Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promoters. Mol Endocrinol. 1993;7:1603–1616. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials